远大医药盘中涨超8%,截至发稿,股价上涨6.75%,现报8.86港元,成交额2.21亿港元。远大医药近期迎来多重利好。公司针对百亿美元规模的脓毒症治疗市场推出的FIC新药STC3141在临床II期研究中取得成功,该产品有望打破脓毒症领域长期缺乏针对性药物的困境,成为重症治疗领域首个具有开创性意义的突破性疗法。此外,公司创新RDC产品TLX591加入国际多中心III期临床试验的申请已经获得国家药监局...
Source Link远大医药盘中涨超8%,截至发稿,股价上涨6.75%,现报8.86港元,成交额2.21亿港元。远大医药近期迎来多重利好。公司针对百亿美元规模的脓毒症治疗市场推出的FIC新药STC3141在临床II期研究中取得成功,该产品有望打破脓毒症领域长期缺乏针对性药物的困境,成为重症治疗领域首个具有开创性意义的突破性疗法。此外,公司创新RDC产品TLX591加入国际多中心III期临床试验的申请已经获得国家药监局...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.